Review
New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease
Affiliations
- PMID: 15741928
Item in Clipboard
Review
New concepts in anti-tumor necrosis factor therapy for inflammatory bowel disease
Rev Gastroenterol Disord.
2005 Winter.
Abstract
Crohn's disease is a T helper type 1 response immune disease characterized by increased production of interleukin-12 tumor necrosis factor-a (TNF-a), and interferon-g. Clinical trials have demonstrated that inhibition of TNF is effective for the treatment of Crohn's disease. Adverse events reported in patients treated with anti-TNF agents include immunogenicity, acute infusion reactions, delayed hypersensitivity-type reactions, autoimmune diseases including drug-induced lupus and demyelination, and infection. This article reviews new concepts in the treatment of Crohn's disease and ulcerative colitis with a variety of anti-TNF biologic therapies: infliximab, adalimumab, CDP870, CDP571, etanercept, and onercept.
Similar articles
-
Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.Nat Clin Pract Gastroenterol Hepatol. 2006 Apr;3(4):220-8. doi: 10.1038/ncpgasthep0447. Nat Clin Pract Gastroenterol Hepatol. 2006. PMID: 16582964 Review.
-
Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease.Curr Gastroenterol Rep. 2003 Dec;5(6):501-5. doi: 10.1007/s11894-003-0040-8. Curr Gastroenterol Rep. 2003. PMID: 14602060 Review.
-
Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.BioDrugs. 2010 Dec 14;24 Suppl 1:3-14. doi: 10.2165/11586290-000000000-00000. BioDrugs. 2010. PMID: 21175228 Review.
-
Strategies for targeting tumour necrosis factor in IBD.Best Pract Res Clin Gastroenterol. 2003 Feb;17(1):105-17. doi: 10.1053/bega.2002.0345. Best Pract Res Clin Gastroenterol. 2003. PMID: 12617886 Review.
-
Transcending conventional therapies: the role of biologic and other novel therapies.Inflamm Bowel Dis. 2001 May;7 Suppl 1:S9-16. doi: 10.1002/ibd.3780070504. Inflamm Bowel Dis. 2001. PMID: 11380043 Review.
Cited by
-
Stem cells as potential therapeutic targets for inflammatory bowel disease.Front Biosci (Schol Ed). 2010 Jun 1;2(3):993-1008. doi: 10.2741/s115. Front Biosci (Schol Ed). 2010. PMID: 20515838 Free PMC article. Review.
-
TNF-alpha and shear stress-induced large artery adaptations.J Surg Res. 2007 Aug;141(2):299-305. doi: 10.1016/j.jss.2006.12.563. Epub 2007 Jun 15. J Surg Res. 2007. PMID: 17574273 Free PMC article.
-
Beneficial effects of Etanercept on experimental necrotizing enterocolitis.Pediatr Surg Int. 2014 Jan;30(1):71-7. doi: 10.1007/s00383-013-3415-4. Epub 2013 Sep 27. Pediatr Surg Int. 2014. PMID: 24072202
-
Dynamics of pro-inflammatory and anti-inflammatory cytokine release during acute inflammation in chronic obstructive pulmonary disease: an ex vivo study.Respir Res. 2008 May 29;9(1):47. doi: 10.1186/1465-9921-9-47. Respir Res. 2008. PMID: 18510721 Free PMC article.
-
Bacterial meningitis associated with infliximab.Pharm World Sci. 2006 Jun;28(3):123-5. doi: 10.1007/s11096-006-9022-x. Epub 2006 Sep 27. Pharm World Sci. 2006. PMID: 17004022